Inverness carries on along acquisition trail
This article was originally published in Clinica
Inverness Medical Innovations has entered an acquisition agreement with protein-based diagnostics specialist Matritech that will see it clinch its sixth purchase of the year. The Matritech buy, expected to close in the fourth quarter of 2007, will cost Inverness $36m in common stock, possibly highlighting that such prolific purchases have taken their toll on the company's financial reserves.
You may also be interested in...
Feature: Public Health England has revealed it is only a week away from approving a COVID-19 antibody test for distribution via Amazon. HBW Insight looks at the race to place the first, government-approved coronavirus home-test on the UK market.
As part of its efforts to preserve patient access to medicines amid the COVID-19 pandemic, Russia is planning to cap drug prices if increases of more than 30% are detected. It will also allow online sales of non-prescription drugs and may also tighten the rules on fake and substandard products.
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the European Union, and updates on EU marketing authorization changes recommended by the CHMP.